Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization

Abstract Neuropathological follow-up of patients with Alzheimer’s disease (AD) who participated in the first clinical trial of Amyloid-β 42 (Aβ42) immunization (AN1792, Elan Pharmaceuticals) has shown that immunization can induce removal of Aβ42 and Aβ40 from plaques, whereas analysis of the cerebra...

Full description

Bibliographic Details
Main Authors: Lieke Jäkel, Delphine Boche, James A. R. Nicoll, Marcel M. Verbeek
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Acta Neuropathologica Communications
Subjects:
Amyloid-β
Aβ43
Cerebral amyloid angiopathy
Alzheimer’s disease
Aβ immunotherapy
Human study
Online Access:http://link.springer.com/article/10.1186/s40478-019-0791-6

Internet

http://link.springer.com/article/10.1186/s40478-019-0791-6

Similar Items